Levothyroxine Treatment During Pregnancy: A Metabolomics Study
Basic & Clinical Pharmacology & Toxicology · 2026-07 · 139 (1)
DOI: 10.1111/bcpt.70246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 22.05.2026. Verfasst von Olli Kärkkäinen und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Thyroxine, Fetal Blood, Pregnancy Complications, Hypothyroidism. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, Avohoidon Tutkimussäätiö.
Abstract (Originalsprache)
Levothyroxine is one of the most prescribed drugs during pregnancy. Our aim was to determine levothyroxine treatment‐associated changes in the metabolite profiles and link these to the health of the newborn. Metabolite profiles of 118 levothyroxine‐treated and 118 healthy control pregnancies were determined with nuclear magnetic resonance‐based metabolomics from (1) umbilical cord blood samples, (2) samples collected during the first trimester and (3) during delivery from the pregnant women. There was a modest negative correlation between cord blood thyroid stimulating hormone (CBTSH) concentrations and Apgar scores at the 1 and 5 min time points in levothyroxine‐treated pregnancies. Furthermore, the concentrations of cord serum metabolites linked with anaerobic glycolysis, for example, lactate, citrate and glycerol, as well as all measured amino acids were negatively associated with Apgar scores. Moreover, cord serum concentrations of lactate, glycerol and alanine were modestly correlated with CBTSH concentrations in the levothyroxine‐treated pregnancies. In the during delivery samples, there was small but significant decrease in cholesteryl esters, cholesterol and phospholipids in small very low‐density lipoprotein in the levothyroxine‐treated pregnancies. In conclusion, levothyroxine treatment during pregnancy was associated with relatively small alterations in the blood metabolite profiles during pregnancy and labour.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
- Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
- Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.
ORCID-Profile: Olli Kärkkäinen, Heidi Sahlman, Leea Keski-Nisula, Jaana Rysä
Förderung
- Horizon 2020 Framework Programme
- Avohoidon Tutkimussäätiö
Zitieren
APA
Kärkkäinen, O., Sahlman, H., Keski-Nisula, L., & Rysä, J. (2026). Levothyroxine Treatment During Pregnancy: A Metabolomics Study. Basic & Clinical Pharmacology & Toxicology, 139(1). https://doi.org/10.1111/bcpt.70246
Vancouver
Kärkkäinen O, Sahlman H, Keski-Nisula L, Rysä J. Levothyroxine Treatment During Pregnancy: A Metabolomics Study. Basic & Clinical Pharmacology & Toxicology. 2026;139(1). doi:10.1111/bcpt.70246
BibTeX
@article{Krkkinen2026,
author = {Kärkkäinen, Olli and Sahlman, Heidi and Keski-Nisula, Leea and Rysä, Jaana},
title = {Levothyroxine Treatment During Pregnancy: A Metabolomics Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {139},
number = {1},
doi = {10.1111/bcpt.70246}
}
EUVIMED